Skip to content
Movie Casting Call
Author:
Pharvaris N.V.
Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026
May 29, 2026
Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 22, 2026
Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update
May 12, 2026
Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 12, 2026
Pharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary Shares
May 8, 2026
Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference
April 20, 2026
←
Previous Page
1
2